Every GLP-1 Medication Available in 2026 (Complete List)

Prices verified May 2026 · Compare GLP-1 Editorial Team

The Complete Landscape

The GLP-1 receptor agonist market has expanded significantly since semaglutide first gained attention for weight loss. As of 2026, there are multiple FDA-approved medications, several in the pipeline, and an active compounded market. Here's every option currently available or approaching approval.

FDA-Approved GLP-1 Medications

Semaglutide

Wegovy (semaglutide 2.4mg) — Novo Nordisk. FDA-approved for chronic weight management in adults with BMI ≥30 (or ≥27 with a weight-related comorbidity). Weekly subcutaneous injection. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events. The most prescribed GLP-1 for weight management.

Ozempic (semaglutide 0.5mg, 1mg, 2mg) — Novo Nordisk. FDA-approved for type 2 diabetes. Same molecule as Wegovy at different doses. Frequently prescribed off-label for weight management, though insurance typically won't cover it for that indication.

Rybelsus (oral semaglutide 3mg, 7mg, 14mg) — Novo Nordisk. The only oral GLP-1 currently FDA-approved, indicated for type 2 diabetes. Lower bioavailability than injectable semaglutide, requiring higher nominal doses. Must be taken on an empty stomach with minimal water.

Tirzepatide

Zepbound (tirzepatide 5mg, 10mg, 15mg) — Eli Lilly. FDA-approved for chronic weight management. Dual GLP-1/GIP agonist. Produced the highest average weight loss of any FDA-approved medication in clinical trials (22.5% in SURMOUNT-1). Weekly subcutaneous injection.

Mounjaro (tirzepatide 2.5mg–15mg) — Eli Lilly. FDA-approved for type 2 diabetes. Same molecule as Zepbound. Commonly prescribed off-label for weight loss.

Older GLP-1 Medications

Saxenda (liraglutide 3mg) — Novo Nordisk. FDA-approved for weight management. Daily injection (vs. weekly for semaglutide/tirzepatide). Less effective than semaglutide or tirzepatide for weight loss, but has a longer safety track record. Generic versions anticipated.

Victoza (liraglutide 1.2mg, 1.8mg) — Novo Nordisk. FDA-approved for type 2 diabetes. Same molecule as Saxenda. Daily injection.

Trulicity (dulaglutide) — Eli Lilly. FDA-approved for type 2 diabetes. Weekly injection. Not commonly used for weight management; less effective for weight loss than semaglutide or tirzepatide.

Byetta/Bydureon (exenatide) — AstraZeneca. One of the earliest GLP-1 receptor agonists. FDA-approved for type 2 diabetes. Rarely used for weight management.

The Pipeline: What's Coming

Orforglipron (Eli Lilly) — Oral small-molecule GLP-1 agonist. Unlike Rybelsus, it doesn't have food/water restrictions and has higher oral bioavailability. NDA filed with FDA; approval could come in 2026–2027. Phase 3 data showed approximately 12.4% weight loss.

CagriSema (Novo Nordisk) — Combination of semaglutide + cagrilintide (an amylin analog). NDA filed December 2025. REDEFINE 1 trial showed 22.7% weight loss. A potential "next-gen" option combining two mechanisms of action.

Retatrutide (Eli Lilly) — Triple agonist (GLP-1/GIP/glucagon). Phase 3 TRIUMPH program ongoing. Phase 2 data showed up to 24.2% weight loss at 48 weeks. Could be the most effective weight loss medication ever developed if Phase 3 data holds.

Survodutide (Boehringer Ingelheim/Zealand) — Dual GLP-1/glucagon agonist. In Phase 3 for MASH (metabolic-associated steatohepatitis) and obesity. Early data showed strong weight loss and liver fat reduction.

Compounded GLP-1 Options

Compounded versions of semaglutide and tirzepatide are available from telehealth providers partnered with 503A and 503B compounding pharmacies. These use the same active pharmaceutical ingredients but are not FDA-approved finished products. Compounded medications are available at significantly lower cost ($146–400/month) compared to brand-name ($1,000+/month).

Start Your GLP-1 Journey